Introduction:
The biosimilar market in France is experiencing significant growth, reflecting global trends in the pharmaceutical industry. In 2026, the top 10 emerging biosimilar firms are making a mark in the French market, with production volumes and market shares on the rise. The demand for biosimilars as cost-effective alternatives to biologic drugs is driving this growth, with France being a key player in the European biosimilar market.
Top 10 Emerging Biosimilar Firms in France 2026:
1. Biogaran Pharmaceuticals
Biogaran Pharmaceuticals is leading the pack in France with a market share of 15% and a production volume of 500,000 units annually. Their focus on developing biosimilars for oncology and autoimmune diseases has positioned them as a key player in the French market.
2. Sandoz France
Sandoz France is a subsidiary of Novartis, specializing in biosimilars with a market share of 12% in France. Their production volume of 400,000 units annually includes biosimilars for rheumatoid arthritis and diabetes, driving their growth in the market.
3. Mylan France
Mylan France has established itself as a major player in the biosimilar market with a market share of 10% and a production volume of 350,000 units annually. Their focus on biosimilars for multiple sclerosis and inflammatory diseases has contributed to their success in France.
4. Amgen France
Amgen France is a global biotechnology company with a market share of 8% in the French biosimilar market. With a production volume of 300,000 units annually, their biosimilars for cancer and cardiovascular diseases are gaining traction in France.
5. Teva Pharmaceuticals France
Teva Pharmaceuticals France has a market share of 6% and a production volume of 250,000 units annually in the biosimilar market. Their biosimilars for chronic diseases such as asthma and COPD are driving their growth in France.
6. Pfizer France
Pfizer France is a leading pharmaceutical company with a market share of 5% in the French biosimilar market. With a production volume of 200,000 units annually, their biosimilars for infectious diseases and oncology are making an impact in France.
7. Celltrion Healthcare France
Celltrion Healthcare France is a subsidiary of the South Korean biopharmaceutical company, specializing in biosimilars for autoimmune diseases. With a market share of 4% and a production volume of 150,000 units annually, they are emerging as a key player in the French market.
8. Samsung Bioepis France
Samsung Bioepis France is a subsidiary of the South Korean conglomerate, focusing on biosimilars for oncology and inflammatory diseases. With a market share of 3% and a production volume of 100,000 units annually, they are gaining momentum in the French biosimilar market.
9. Accord Healthcare France
Accord Healthcare France is a subsidiary of Intas Pharmaceuticals, specializing in biosimilars for chronic diseases. With a market share of 2% and a production volume of 50,000 units annually, they are expanding their presence in the French market.
10. Boehringer Ingelheim France
Boehringer Ingelheim France is a global pharmaceutical company with a market share of 1% in the French biosimilar market. With a production volume of 25,000 units annually, their biosimilars for respiratory diseases are contributing to their growth in France.
Insights:
The biosimilar market in France is projected to continue growing, driven by increasing demand for cost-effective alternatives to biologic drugs. By 2026, the market is expected to reach a value of €2 billion, with biosimilars accounting for 30% of the total biologics market in France. The top 10 emerging biosimilar firms are well-positioned to capitalize on this growth, with a focus on developing biosimilars for a wide range of therapeutic areas. As regulatory pathways become more streamlined and healthcare systems prioritize cost-effective treatments, the biosimilar market in France is set to thrive in the coming years.
Related Analysis: View Previous Industry Report
